NCT05086614View on ClinicalTrials.gov

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

2,500

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Stage II Colorectal CancerStage III Colorectal Cancer

Interventions

DRUG

Thymosin Alpha1

Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT05086614 - Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer | Biotech Hunter | Biotech Hunter